Core Viewpoint - Aptose Biosciences (APTO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is expected to lead to increased buying pressure and a rise in stock price [1][2]. Earnings Estimates and Stock Price Impact - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, influencing their buying and selling decisions, which in turn affects stock prices [3]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [4]. - The system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks are considered for strong ratings, indicating superior earnings estimate revisions [6]. Earnings Estimate Revisions for Aptose Biosciences - For the fiscal year ending December 2024, Aptose Biosciences is expected to report earnings of -$3.31 per share, reflecting a 56.3% change from the previous year [5]. - Over the past three months, the Zacks Consensus Estimate for Aptose has increased by 41.6%, indicating a positive trend in earnings estimates [5]. Positioning in Zacks Coverage - The upgrade to Zacks Rank 2 places Aptose Biosciences in the top 20% of Zacks-covered stocks, suggesting potential for upward movement in stock price in the near term [7].

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Conference Call March 26, 2024 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants Soumit Roy - Jones Research Operator Good afternoon. My name is Jonathan and I will be your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Biosciences Inc. (Exact name of Registrant as specified in its Charter) Canada 98-1136802 (State or other jurisdiction o ...

Financial Performance - Aptose reported a net loss of $51.2 million for the year ended December 31, 2023, an increase of $9.4 million compared to a net loss of $41.8 million in 2022[12]. - Cash and cash equivalents decreased to $9.3 million as of December 31, 2023, down from $47.0 million at the end of 2022[10]. - Total shareholders' equity decreased to $(2.9) million as of December 31, 2023, compared to $37.7 million in 2022[10]. Research and Development - Research and development expenses rose to $36.8 million in 2023, up $8.7 million from $28.1 million in 2022, primarily due to increased costs associated with the tuspetinib program[14]. - Tuspetinib achieved a complete response/complete response with partial hematologic recovery (CR/CRh) rate of 36% among patients naive to venetoclax at the recommended Phase 2 dose of 80 mg[5]. - The G3 formulation of luxeptinib demonstrated approximately 10-fold better absorption compared to the original G1 formulation, achieving desired plasma exposure levels[7]. - The company plans to initiate a pilot triplet study of tuspetinib, venetoclax, and a hypomethylating agent in frontline therapy for newly diagnosed AML patients in Summer 2024[8]. Capital and Funding - The company completed a public offering on January 30, 2024, raising approximately $9.7 million from the sale of 5,649,122 common shares at $1.71 per share[3]. - A private placement with Hanmi Pharmaceutical on January 31, 2024, generated $4 million, with shares sold at $1.90 each, an 11% premium over the public offering price[4]. Risks and Uncertainties - The company acknowledges significant risks and uncertainties that could impact future results, including capital acquisition for research and operations[23]. - Early-stage drug development risks include demonstrating efficacy, development time/cost, and regulatory approval processes[23]. - There is a potential risk of new manufacturers failing to produce acceptable GMP batches in sufficient quantities[23]. - Unexpected manufacturing defects are highlighted as a significant risk factor[23]. - The company does not intend to update forward-looking statements unless required by law, indicating a cautious approach to investor communications[24]. - Investors are advised not to overly rely on forward-looking statements due to inherent uncertainties[24]. Administrative Expenses - General and administrative expenses increased to $15.6 million in 2023, up from $14.5 million in 2022, driven by higher salaries and professional fees[17].

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:li ...

Core Viewpoint - Aptose Biosciences Inc. is set to report its financial results for Q4 and the full year of 2023 on March 26, 2024, along with a corporate update [1]. Group 1: Financial Reporting - The financial results will be disclosed after the market closes on March 26, 2024 [1]. - Analysts can participate in a Q&A session by pre-registering for the conference call [3]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The company has a pipeline of small molecule cancer therapeutics aimed at providing single-agent efficacy and enhancing the effectiveness of other anti-cancer therapies without overlapping toxicities [4]. - Two clinical-stage oral kinase inhibitors are under development: tuspetinib (HM43239) for relapsed or refractory acute myeloid leukemia (AML) and luxeptinib (CG-806) for relapsed or refractory hematologic malignancies [4].

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the "Public Offering") of 5,649,122 common shares of the Company (the "Common Shares") and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Com ...

Aptose Biosciences (NASDAQ:APTO) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company’s shares.Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share. That has it expecting gross proceeds of $8.4 million from the stock offering.To go along with this, each share of APTO stock sold in the offering comes with one warrant. These warrants are for the purchase of another share of the company’s stock. The ex ...

Core Viewpoint - Aptose Biosciences Inc. has announced a public offering of approximately 4.9 million common shares at a price of $1.71 per share, aiming to raise about $8.4 million before expenses [1][3] Group 1: Public Offering Details - The public offering consists of 4,912,280 common shares priced at $1.71 each, with warrants included for the same price [1] - Gross proceeds from the public offering are expected to be around $8.4 million, with underwriters having a 30-day option to purchase an additional 736,842 shares and/or warrants [1][3] - The public offering is anticipated to close on or about January 30, 2024, pending customary closing conditions [3] Group 2: Private Placement Details - A concurrent private placement of $4 million with Hanmi Pharmaceutical will occur, with Hanmi acquiring 19.97% of Aptose's outstanding shares post-placement at a price of $1.90 per share, an 11% premium over the public offering price [2] - Hanmi will also receive warrants to purchase common shares at $1.71 per share [2] - The private placement is expected to close on or about January 31, 2024, subject to customary closing conditions [3] Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to support clinical trials for tuspetinib, manufacture clinical supplies, and for working capital and general corporate purposes [3] Group 4: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [7] - The lead product, tuspetinib, is being studied as a treatment for relapsed or refractory acute myeloid leukemia (AML) [7]

Table of Contents As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. 333-275870 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTOSE BIOSCIENCES INC. (Exact Name of Registrant As Specified In Its Charter) (State or other jurisdiction of incorporation or organization) Canada 2836 98-1136802 (Primary Standard Industrial Classification Code Number) (I.R.S. Employe ...